Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection

2021 ◽  
Author(s):  
Samer A. Naffouje ◽  
Arvind Sabesan ◽  
Dae-Won Kim ◽  
Estrella Carballido ◽  
Jessica Frakes ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Patient Selection ◽  
Ductal Adenocarcinoma ◽  
Adjuvant Chemoradiotherapy

scholarly journals Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Raju Kandimalla ◽  
Tadanobu Shimura ◽  
Saurav Mallik ◽  
Fuminori Sonohara ◽  
Susan Tsai ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Mirna Signature ◽  
Serum Mirna

scholarly journals Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management

2021 ◽  
Vol 19 (4) ◽  
pp. 459-467
Author(s):  
Zhi Ven Fong ◽  
Cristina R. Ferrone
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Metastatic Disease ◽  
Patient Selection ◽  
Selection Process ◽  
Locally Advanced ◽  
Late Presentation ◽  
Ductal Adenocarcinoma ◽  
Curative Intent ◽  
Response To Chemotherapy ◽  
Multiagent Chemotherapy

Because of the biologic aggressiveness and late presentation of pancreatic ductal adenocarcinoma (PDAC), up to 80% of patients have locally advanced or metastatic disease at presentation. The success of multiagent chemotherapy regimens in the management of metastatic disease has been translated to patients with locally advanced PDAC. Both FOLFIRINOX (fluorouracil/folinic acid/irinotecan/oxaliplatin) and gemcitabine/nab-paclitaxel are used to downstage locally advanced PDAC to render it eligible for resection with curative intent. This paradigm shift has significantly expanded the pool of patients who are eligible for resection with curative intent. However, the generalizability of present studies and the patient selection process are unclear. This article provides an evidence-based review of patient selection considerations and management algorithms, and details our institution’s approach to patients with locally advanced PDAC after preoperative chemotherapy.

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma

2000 ◽  
Vol 15 (11) ◽  
pp. 1333-1338 ◽  
Author(s):  
Koji Uno ◽  
Takeshi Azuma ◽  
Masatsugu Nakajima ◽  
Kenjiro Yasuda ◽  
Takanobu Hayakumo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Significance ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Cathepsin E
Sign in / Sign up

Export Citation Format

Share Document